Assessment of Consumer Knowledge of New Sunscreen Labels
UV-A radiation is associated with accelerated skin aging, while UV-B exposure is associated with sunburns.
1 Exposure to both types of radiation is a major risk factor for the development of skin cancer. 1 By protecting the skin from UV light, sunscreen protects against these negative sequelae of sun exposure. [2] [3] [4] In 2011, the US Food and Drug Administration announced new regulations for sunscreen labels to emphasize the importance of protection against both UV-A and UV-B radiation, now known as broad-spectrum protection. 5, 6 In this survey study, we assessed consumer comprehension of sunscreen labels and knowledge of general sun protective behaviors.
Methods | Following approval by the Northwestern University Institutional Review Board, 114 participants who attended the Northwestern Medicine dermatology clinic between June 1 and August 31, 2014, and gave verbal consent were anonymously surveyed. Participants were asked to answer questions regarding their demographics, Fitzpatrick skin type, sunscreen purchasing behaviors, and understanding of the language commonly used on sunscreen labels. Associations between 2 factors were assessed using the Yates χ 2 test with P = .05 considered significant.
Results | The results of our analysis are summarized in Table 1 and ) understood that sun avoidance is superior to sun protection in skin cancer prevention. Interestingly, participants who indicated "highest SPF available" as an important factor in their sunscreen purchasing decision were less likely to answer this question correctly compared with those who did not consider SPF value to be an important factor (P < .05). Furthermore, only 63 participants (55.3%) correctly identified the amount of sunscreen needed to cover the entire body in order to achieve the advertised level of sun protection.
Finally, participants were presented with a sunscreen label that designated UV-A protection as a star rating system (out of 4 stars) and UV-B protection as an SPF value. When given this sunscreen label, most participants were able to correctly determine the level of UV-A (90 [78.9%]) and UV-B (101 [88.6%]) protection.
Discussion | Despite the recent changes in labeling mandated by the US Food and Drug Administration, this survey study suggests that the terminology on sunscreen labels may still be confusing to consumers. Furthermore, consumers may hold misconceptions about the factors important in a sunscreen, including a common overreliance on the SPF value. There is an ongoing need for physicians to educate their patients about the need for protection against both UV-A and UV-B radiation in preventing skin cancer and sunburns.
A new metric may be needed to better reflect the performance of current sunscreens. Given that the majority of participants were able to correctly interpret a sunscreen label in which UV-A and UV-B protection were separately designated, this approach seems promising for its use in improving consumer understanding of sunscreen labels and their ability to make informed sunscreen purchasing decisions. 
Efficacy of Vinblastine in Primary Cutaneous Anaplastic Large Cell Lymphoma
Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a rare primary cutaneous CD30 + T-cell lymphoproliferative disorder that affects patients at a median age of 60 years. The disease presents as localized or less frequently disseminated nodules, plaques, or ulcers that mostly affect limbs. Prognosis is favorable (5-year overall survival, >80%). According to the consensus recommendations, 1 surgical excision or radiotherapy is recommended for localized lesions. For multifocal lesions, low-dose methotrexate is commonly used with a favorable response.
2 Multiagent chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, is effective but because of adverse effects and a high rate of relapses is reserved for disseminated relapse and extracutaneous dissemination. Brentuximab vedotin has excellent effectiveness, 3 but its use remains off label, expensive, and sometimes responsible for neuropathy and severe infectious complications. Consequently, therapeutic recommendations are lacking for patients with methotrexate failure, especially for older patients. We report a series of 7 patients who received vinblastine as single-agent chemotherapy for relapsing multifocal C-ALCL.
Methods | We retrospectively collected files of patients with C-ALCL (without lymph node invasion) who received vinblastine as monotherapy in the dermatology departments of the institution members of the Cutaneous Lymphoma French Study Group. Institutional review board approval and informed consent were not required because this is a retrospective study.
Results | Seven patients (4 men) in their 30s to 90s (4 patients ≥70 years old) were included. The TNM stage 4 was T1 in 1 case, T2 in 4 cases, and T3 in 2 cases. Lower limbs were involved in 6 cases. Median time from diagnosis was 5 years (range, 0.3-19 years). Six patients had previously received treatments with topical corticosteroids (n = 1), surgery (n = 1), radiotherapy (n = 4), methotrexate (n = 4), and/or multiagent chemotherapy (n = 3). One patient had contraindication to methotrexate (chronic renal insufficiency with anemia). All patients received 6 mg/m 2 of vinblastine twice a month, except for 1 patient, who received 4 mg/m 2 . All patients had partial (>75%) or complete remission after a median of 4 infusions ( Figure) . Four patients experienced hematologic adverse effects: 3 had neutropenia (lowest neutrophil count was 153/μL [to convert to ×10 9 /L, multiply by 0.001], 2 patients received granulocyte-colony stimulating factor), and 2 patients had anemia (lowest hemoglobin value was 7.3 g/dL [to convert to grams per liter, multiply by 10], 1 patient underwent transfusion). There were no infectious complications or neuropathy.
Six patients experienced relapse after a median progression-free survival of 6 months (range, 3.5-28 months; median number of infusions, 10; range, 6-55) but relapse in 5 cases was limited to a slow worsening of previous lesions. When relapse occurred after discontinuation of treatment (n = 1) or after a longer interval between infusions (4 weeks, n = 1), rechallenge was effective. Furthermore, for the patient who began taking vinblastine at 4 mg/m 2 , increasing the dose to 6 mg/m 2 was effective. However, in 3 patients, treatment was modified because of relapse (with the administration of brentuximab, radiotherapy, or autograft).
Discussion | Considering the age of patients affected by C-ALCL and the good prognosis of the disease, therapy with a favorable benefit to risk ratio is needed. Despite little strong evidence, low-dose methotrexate seems to be a first-line therapy with a very good safety profile, especially for older patients. 2 Brentuximab therapy was effective for CD30 + cutaneous lymphomas in a phase 2 study with an overall response rate of 70% and progression-free survival of 150 days 3 and also seems promising in other types of cutaneous T-cell lymphomas in an allogenic stem cell transplantation plan.
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However, its use is limited by its cost and the risk of neuropathy and severe infectious complications. We report, for the first time to our knowledge, the efficacy of vinblastine as monotherapy for C-ALCL. Vinblastine is a vinca alkaloid commonly used in dermatology as a single agent in the treatment of Kaposi sarcoma with good tolerance, even in older patients. Vinblastine is successfully used as monotherapy for pediatric systemic ALCL 6 but, to our knowledge, has never been reported for primary cutaneous lymphomas. 
